Immunomedics appointed Harout Semerjian as CEO at the beginning of April, ahead of a busy period for the company – as it navigates the launch of its lead product, Trodelvy (sacituzumab govitecan).
Semerjian officially took on the position of CEO and executive chairman on April 16, joining the company from Ipsen, where he had acted as chief commercial officer. Prior to his time at Ipsen, he had a 13-year career at Novartis, spanning various roles and ending his time at the Swiss giant as head of the company’s hematology business.
Trodelvy was granted accelerated approval by the US Food and Drug Administration a week after Semerjian entered the role and Immunomedics then announced that it would launch a public offering, seeking to raise $350m (€322m) to fund the launch of the product and to scale up manufacturing.
“I am honored and excited to be joining Immunomedics at this critical time. The company has a unique antibody-drug conjugate platform and I share the board’s belief that sacituzumab govitecan has the potential to offer cancer patients a viable treatment option, as demonstrated in recent clinical studies in triple-negative breast cancer, urothelial cancer and hormone-receptor positive/HER2-negative breast cancer,” said Semerjian.